YKYong-Sam Kim

Yong-Sam Kim

*This is an algorithmically generated author record based on publicly available information.

Yong-Sam Kim has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Jeong-Heon Ko

    KRIBB School of Bioscience, Korea University of Science and Technology, Daejeon, Republic of Korea

    14 shared publications
  • Do Yon Kim

    GenKOre, Daejeon, Republic of Korea

    10 shared publications
  • Su Bin Moon

    Genome Editing Research Center, Korea Research Institute of Bioscience & BioTechnology, Daejeon, Republic of Korea

    8 shared publications
  • Hyun Jung Chin

    Genome Editing Research Center, KRIBB, Daejeon, Republic of Korea

    5 shared publications
  • Jeong Gu Kang

    Genome Editing Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon, 34141, Korea

    5 shared publications
  • Jeong Mi Lee

    Genome Editing Research Center, KRIBB, Daejeon, Republic of Korea

    5 shared publications

Latest Publications

  • Open Access

    Author Correction: Hypercompact adenine base editors based on a Cas12f variant guided by engineered RNA

    by Do Yon Kim, Yuhee Chung, Yujin Lee, Dongmin Jeong, Kwang-Hyun Park, Hyun Jung Chin, Jeong Mi Lee, Seyeon Park, Sumin Ko, Jeong-Heon Ko, et al.


  • Hypercompact adenine base editors based on a Cas12f variant guided by engineered RNA

    by Do Yon Kim, Yuhee Chung, Yujin Lee, Dongmin Jeong, Kwang-Hyun Park, Hyun Jung Chin, Jeong Mi Lee, Seyeon Park, Sumin Ko, Jeong-Heon Ko, et al.

    Transposon-associated transposase B (TnpB) is deemed an ancestral protein for type V, Cas12 family members, and the closest ancestor to UnCas12f1. Previously, we reported a set of engineered guide RNAs supporting high indel efficiency for Cas12f1 in human cells. Here we suggest a new technology whereby the engineered guide RNAs also manifest high-efficiency programmable endonuclease activity for TnpB. We have termed this technology TaRGET (TnpB-augment RNA-based Genome Editing Technology). Having this feature in mind, we established TnpB-based adenine base editors (ABEs). A Tad–Tad mutant (V106W, D108Q) dimer fused to the C terminus of dTnpB (D354A) showed the highest levels of A-to-G conversion. The limited targetable sites for TaRGET-ABE were expanded with engineered variants of TnpB or optimized deaminases. Delivery of TaRGET-ABE also ensured potent A-to-G conversion rates in mammalian genomes. Collectively, the TaRGET-ABE will contribute to improving precise genome-editing tools that can be delivered by adeno-associated viruses, thereby harnessing the development of clustered regularly interspaced short palindromic repeats (CRISPR)-based gene therapy.


  • Open Access

    AAV-deliverable hypercompact adenine base editors based on transposase B guided by engineered RNA

    by Do Yon Kim, Yuhee Chung, Yujin Lee, Dongmin Jeong, Kwang-Hyun Park, Hyun Jung Chin, Jeong Mi Lee, Seyeon Park, Sumin Ko, Jeong-Heon Ko, et al.

    Transposon-associated transposase B (TnpB) is deemed an ancestral protein for type V, Cas12 family members, and the closest ancestor to UnCas12f1 due to its high sequence similarity. Previously, we reported a set of engineered guide RNAs supporting high indel efficiency for Cas12f1 in human cells. Here, we suggest a new technology whereby the engineered gRNAs also manifest highly efficiency programmable endonuclease activity for TnpB, termed TaRGET (TnpB-augment RNA-based Genome Editing Technology). Having this feature in mind, we established TnpB-based adenine base editors. A codon-optimized Tad-Tad mutant (V106W, D108Q) dimer fused to the C-terminus of dTnpB (D354A) showed the highest levels of A-to-G conversion. The limited targetable sites for TaRGET-ABE were expanded by either developing several PAM variants of TnpB or by engineering TnpB and optimizing deaminases at PAM-distal and PAM-proximal sites, respectively. When delivered by AAV, the TaRGET-ABE showed potent A-to-G conversion rates in human cells. Collectively, the TaRGET-ABE will contribute to improving precise genome-editing tools that can be delivered by AAV, thereby harnessing the development of CRISPR-based gene therapy.

  • Top Cited Papers
    Open Access

    Efficient CRISPR editing with a hypercompact Cas12f1 and engineered guide RNAs delivered by adeno-associated virus

    by Do Yon Kim, Jeong Mi Lee, Su Bin Moon, Hyun Jung Chin, Seyeon Park, Youjung Lim, Daesik Kim, Taeyoung Koo, Jeong-Heon Ko, Yong-Sam Kim

    Gene therapy would benefit from a miniature CRISPR system that fits into the small adeno-associated virus (AAV) genome and has high cleavage activity and specificity in eukaryotic cells. One of the most compact CRISPR-associated nucleases yet discovered is the archaeal Un1Cas12f1. However, Un1Cas12f1 and its variants have very low activity in eukaryotic cells. In the present study, we redesigned the natural guide RNA of Un1Cas12f1 at five sites: the 5′ terminus of the trans-activating CRISPR RNA (tracrRNA), the tracrRNA–crRNA complementary region, a penta(uridinylate) sequence, the 3′ terminus of the crRNA and a disordered stem 2 region in the tracrRNA. These optimizations synergistically increased the average indel frequency by 867-fold. The optimized Un1Cas12f1 system enabled efficient, specific genome editing in human cells when delivered by plasmid vectors, PCR amplicons and AAV. As Un1Cas12f1 cleaves outside the protospacer, it can be used to create large deletions efficiently. The engineered Un1Cas12f1 system showed efficiency comparable to that of SpCas9 and specificity similar to that of AsCas12a.


  • Open Access

    Detection of Infectious Viruses Using CRISPR-Cas12-Based Assay

    by Chandana S. Talwar, Kwang-Hyun Park, Woo-Chan Ahn, Yong-Sam Kim, Oh Seok Kwon, Dongeun Yong, Taejoon Kang, Euijeon Woo

    The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease-19 (COVID-19), has severely influenced public health and economics. For the detection of SARS-CoV-2, clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein (Cas)-based assays have been emerged because of their simplicity, sensitivity, specificity, and wide applicability. Herein, we have developed a CRISPR-Cas12-based assay for the detection of SARS-CoV-2. In the assay, the target amplicons are produced by isothermal reverse transcription recombinase polymerase amplification (RT-RPA) and recognized by a CRISPR-Cas12a/guide RNA (gRNA) complex that is coupled with the collateral cleavage activity of fluorophore-tagged probes, allowing either a fluorescent measurement or naked-eye detection on a lateral flow paper strip. This assay enables the sensitive detection of SARS-CoV-2 at a low concentration of 10 copies per sample. Moreover, the reliability of the method is verified by using nasal swabs and sputum of COVID-19 patients. We also proved that the current assay can be applied to other viruses, such as Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV), with no major changes to the basic scheme of testing. It is anticipated that the CRISPR-Cas12-based assay has the potential to serve as a point-of-care testing (POCT) tool for a wide range of infectious viruses.


  • Open Access

    Full-fledged gene-editing payload for AAV delivery built on guide RNA-remodeled miniature type V-F CRISPR

    by Yong-Sam Kim, Do Yon Kim, Jeong Mi Lee, Su Bin Moon, Hyun Jung Chin, Seyeon Park, Youjung Lim, Jeong-Heon Ko

    The authors have requested that this preprint be removed from Research Square.

  • Open Access

    Highly efficient and safe genome editing by CRISPR-Cas12a using CRISPR RNA with a ribosyl-2′-O-methylated uridinylate-rich 3′-overhang in mouse zygotes

    by Dae-In Ha, Jeong Mi Lee, Nan-Ee Lee, Daesik Kim, Jeong-Heon Ko, Yong-Sam Kim

    The CRISPR-Cas12a system has been developed to harness highly specific genome editing in eukaryotic cells. Given the relatively small sizes of Cas12a genes, the system has been suggested to be most applicable to gene therapy using AAV vector delivery. Previously, we reported that a U-rich crRNA enabled highly efficient genome editing by the CRISPR-Cas12a system in eukaryotic cells. In this study, we introduced methoxyl modifications at C2 in riboses in the U-rich 3′-overhang of crRNA. When mixed with Cas12a effector proteins, the ribosyl-2′-O-methylated (2-OM) U-rich crRNA enabled improvement of dsDNA digestibility. Moreover, the chemically modified U-rich crRNA achieved very safe and highly specific genome editing in murine zygotes. The engineered CRISPR-Cas12a system is expected to facilitate the generation of various animal models. Moreover, the engineered crRNA was evaluated to further improve a CRISPR genome editing toolset.


  • Open Access

    Aglycosylated antibody-producing mice for aglycosylated antibody-lectin coupled immunoassay for the quantification of tumor markers (ALIQUAT)

    by Nan-Ee Lee, Sun Hee Kim, Dae-Yeul Yu, Eui-Jeon Woo, Myung-Il Kim, Gi-Sang Seong, Sun Min Lee, Jeong-Heon Ko, Yong-Sam Kim

    Targeting aberrant glycoforms has been validated for in vitro cancer diagnostic development, and several assays are currently in routine clinical use. Because N-glycans in Fc region of antibodies show cross-reactivity with various lectins, high-quality aglycosylated antibodies are exceptionally important for immunoassay platform-based quantitative measurements. Previously, aglycosylated antibody acquisition relied on incomplete, uneconomical and onerous enzymatic and chemical methods. Here, we edited four murine immunoglobulin G genes using adenine base-editing and homology-directed recombination (HDR)-mediated gene editing methods to generate aglycosylated antibody-producing mice. Resulting aglycosylated antibodies showed required analytical performances without compromised protein stability. Thus, this aglycosylated monoclonal antibody-lectin coupled immunoassay for the quantification of tumour markers (ALIQUAT) method can provide a robust, versatile and accessible immunoassay platform to quantify specific glycoforms in precision cancer diagnostics. Moreover, the engineered mice can be used as a host to produce various aglycosylated antibodies in a convenient and robust fashion, thereby expanding in vitro diagnostic development opportunities that utilize glycoforms as a disease-specific biomarkers.


  • Open Access

    Unbiased investigation of specificities of prime editing systems in human cells

    by Do Yon Kim, Su Bin Moon, Jeong-Heon Ko, Yong-Sam Kim, Daesik Kim

    Prime editors (PEs) enable targeted precise editing, including the generation of substitutions, insertions and deletions, in eukaryotic genomes. However, their genome-wide specificity has not been explored. Here, we developed Nickase-based Digenome-seq (nDigenome-seq), an in vitro assay that uses whole-genome sequencing to identify single-strand breaks induced by CRISPR (clustered regularly interspaced short palindromic repeats)-Cas9 (CRISPR-associated protein 9) nickase. We used nDigenome-seq to screen for potential genome-wide off-target sites of Cas9 H840A nickase, a PE component, targeted to nine human genomic sites. Then, using targeted amplicon sequencing of off-target candidates identified by nDigenome-seq, we showed that only five off-target sites showed detectable PE-induced modifications in cells, at frequencies ranging from 0.1 to 1.9%, suggesting that PEs provide a highly specific method of precise genome editing. We also found that PE specificity in human cells could be further improved by incorporating mutations from engineered Cas9 variants, particularly eSpCas9 and Sniper Cas9, into PE.